Understanding CLDN11: Potential Drug Targets and Biomarkers (G5010)

Target Name: CLDN11

NCBI ID: G5010

CLDN11

Understanding CLDN11: Potential Drug Targets and Biomarkers

Claudin 11 (CLDN11) is a protein that is expressed in the endothelial cells of the body. It plays a critical role in cell-cell adhesion and has been implicated in various diseases, including heart disease, cancer, and neurodegenerative disorders.

Drug Targeting

Due to its unique structure and various biological functions, CLDN11 has become a promising drug target for various diseases. Researchers have identified several potential drug targets for CLDN11, including:

1. Targeting Claudin 11 expression: The first drug target for CLDN11 is to target the expression of CLDN11 in endothelial cells. Drugs that can inhibit the expression of CLDN11 have been shown to reduce the growth of cancer cells and improve the delivery of cancer vaccines to the tumor site.
2. Targeting CLDN11-mediated signaling pathways: CLDN11 has been shown to play a role in various signaling pathways, including the TGF-β pathway and the Wnt pathway. Drugs that can inhibit these signaling pathways may have potential therapeutic effects on various diseases.
3. Targeting CLDN11-mediated cellular processes: CLDN11 has been shown to be involved in various cellular processes, including cell adhesion, migration, and invasion. Drugs that can inhibit these processes may have potential therapeutic effects on various diseases.

Biomarker

Another potential use of CLDN11 as a drug target is its potential as a biomarker for various diseases. CLDN11 has been shown to be expressed in various types of cancer, including breast, ovarian, and prostate cancer. Additionally, high levels of CLDN11 have been shown to be associated with various diseases, including heart disease and neurodegenerative disorders.

Importance of CLDN11 research

Understanding the role of CLDN11 in various diseases is important for the development of new treatments. By targeting CLDN11 as a drug target, researchers may be able to improve the treatment outcomes for various diseases. Additionally, the study of CLDN11 as a biomarker may have implications for early disease detection and personalized medicine.

Conclusion

In conclusion, CLDN11 is a protein that has the potential to be a drug target or biomarker for various diseases. The study of its role in cell-cell adhesion, signaling pathways, and cellular processes is ongoing, and its potential as a drug target and biomarker is being investigated. Further research is needed to fully understand the role of CLDN11 in various diseases and to develop effective treatments.

Protein Name: Claudin 11

Functions: Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity

The "CLDN11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLDN11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets